Eli Lilly and Company vs Novo Nordisk A/S — Stock Comparison
Q·Score Breakdown
8.2
Buy
Overall
6.1
Hold
Quality
Health
Growth
Valuation
Sentiment
LLY
Earnings growing 51% year-over-year on 43% revenue growth.
NVO
High-quality business with 61% return on equity and 33% profit margins.
⚠ revenue declining 8% year-over-year.
Analyst Consensus
BUY
Target $1202.34 (+30.4%)
29 analysts
HOLD
Target $46.57 (+9.8%)
12 analysts
Fundamentals
LLY
NVO
40.1×
Trailing P/E
11.8×
21.9×
Forward P/E
12.3×
31.7%
Profit Margin
33.1%
83.0%
Gross Margin
82.4%
101.2%
ROE
60.7%
42.6%
Revenue Growth
-7.6%
51.4%
Earnings Growth
-4.7%
0.50
Beta
0.27
—
Price / Book
—
$824.0B
Market Cap
$188.1B
$624 – $1,134
52-Week Range
$35 – $81
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.